Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch & Lomb CorpBLCO · Entity 3756 | EVP & Chief Legal Officer | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch & Lomb Corp
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 264,241 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Grant · Acquired 33,557 · Balance 264,241 F1: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allergan plc
Report date May 08, 2020 · Filed May 11, 2020
Section 16 reporting ended · disclosed 2020-05-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-08 · Disposition to issuer · Disposed 17,629.307 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-05-08 · Disposition to issuer · Disposed 16,800 · Balance 0 F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $224.00 · Expires 2023-05-08 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-08 · Disposition to issuer · Disposed 16,524 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $103.79 · Expires 2020-08-06 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-05-08 · Disposition to issuer · Disposed 3,852 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2020-08-06 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-05-08 · Disposition to issuer · Disposed 509 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $103.79 · Expires 2020-08-06 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-05-08 · Disposition to issuer · Disposed 9,750 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $196.16 · Expires 2020-08-06 | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-05-08 · Disposition to issuer · Disposed 12,304 · Balance 0 F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-05-08 · Disposition to issuer · Disposed 17,670 · Balance 0 F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
F3: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
F4: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.
F5: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 20:32 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 33,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001860742-26-000090 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,241 F1 · shares: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date. Read SEC document |
| April 24, 2026 Filed Apr 27, 2026 20:42 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | Tax withholdingCommon Shares, No Par Value | 15,806 | $15.82 | $250,050.92 |
DisclosureSEC source: 0001860742-26-000057 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,684 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:23 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001860742-26-000056 · form4.xml · nonDerivative · entry 2 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,490 F3 · shares: Represents matching restricted share units ("MRSUs") granted to the reporting person in connection with the open market purchase of common shares reported on Table I above, pursuant to the issuer's matching share program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the reporting person's continued service (except in limited circumstances). Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:23 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | PurchaseCommon Shares, No Par Value | 14,600 | $17.15 | $250,331.60 |
DisclosureSEC source: 0001860742-26-000056 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,890 F1 · shares: These shares are held by the reporting person's self-directed IRAs. F2 · price: Reflects a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.101 to $17.20 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 22:46 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | Tax withholdingCommon Shares, No Par Value | 2,461 | $18.30 | $45,036.30 |
DisclosureSEC source: 0001860742-26-000043 · form4.xml · nonDerivative · entry 2 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,290 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:46 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | Tax withholdingCommon Shares, No Par Value | 3,395 | $18.49 | $62,773.55 |
DisclosureSEC source: 0001860742-26-000043 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,751 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:13 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 52,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001860742-26-000033 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,146 F1 · shares: Reflects the grant of restricted share units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. Read SEC document |
| April 24, 2025 Filed Apr 25, 2025 20:05 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | Tax withholdingCommon Shares, No Par Value | 9,781 | $13.89 | $135,858.09 |
DisclosureSEC source: 0001127602-25-012621 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,576 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:27 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantNon-Qualified Stock Options (right to purchase) · Derivative | 96,566 | $15.86 Strike: $15.86 | $1,531,536.76 |
DisclosureSEC source: 0001127602-25-007270 · form4.xml · derivative · entry 2 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,566 Underlying: Common Shares, No Par Value · 96,566 shares Expires not disclosed F2 · shares: Reflects the grant of stock options to purchase common shares under the Plan. F3 · derivative.exercise_date: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4 · derivative.expiration_date: The stock options will expire on the tenth anniversary of the grant date. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:27 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 40,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-007270 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,357 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 21:12 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | Tax withholdingCommon Shares, No Par Value | 4,402 | $17.83 | $78,487.66 |
DisclosureSEC source: 0001127602-24-030050 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,817 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 20:08 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | Tax withholdingCommon Shares, No Par Value | 9,838 | $14.90 | $146,586.20 |
DisclosureSEC source: 0001127602-24-013447 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,219 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:22 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantNon-Qualified Stock Options (right to purchase) · Derivative | 101,626 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0001127602-24-007872 · form4.xml · derivative · entry 2 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,626 Underlying: Common Shares, No Par Value · 101,626 shares Expires not disclosed F2 · shares: Reflects the grant of stock options to purchase common shares under the Plan. F3 · derivative.exercise_date: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4 · derivative.expiration_date: The stock options will expire on the tenth anniversary of the grant date. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:22 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 33,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007872 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,057 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:34 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantNon-Qualified Stock Options (right to purchase) · Derivative | 429,184 | $0.00 Strike: $17.50 | $0.00 |
DisclosureSEC source: 0001127602-23-014768 · form4.xml · derivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,184 Underlying: Common Shares, No Par Value · 429,184 shares Expires 2033-05-04 F1 · derivative.exercise_date: Reflects an award of stock options to purchase common shares granted to the reporting person under the Amended and Restated Bausch + Lomb Corporation 2022 Omnibus Incentive Plan on May 4, 2023. Each stock option reflects the right to purchase one common share, subject to the terms of the Plan and the applicable award agreement. The stock options are scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject generally to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 21:20 UTC | Bausch & Lomb Corp BLCO · Entity 3756 | GrantCommon Shares, No Par Value | 120,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013581 · form4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,500 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Amended and Restated Bausch + Lomb Corporation 2022 Omnibus Incentive Plan which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. Read SEC document |
| May 08, 2020 Filed May 11, 2020 21:48 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerPerformance Stock Units · Derivative | 17,670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012754 · doc4.xml · derivative · entry 8 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,670 shares Expires not disclosed F5 · derivative.exercise_price: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). F5 · price: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). F5 · derivative.exercise_date: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). F5 · derivative.expiration_date: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). Read SEC document |
| May 08, 2020 Filed May 11, 2020 21:48 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerStock Options · Derivative | 12,304 | $0.00 Strike: $196.16 | $0.00 |
DisclosureSEC source: 0000899243-20-012754 · doc4.xml · derivative · entry 7 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,304 shares Expires 2020-08-06 F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. Read SEC document |
| May 08, 2020 Filed May 11, 2020 21:48 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerStock Options · Derivative | 9,750 | $0.00 Strike: $103.79 | $0.00 |
DisclosureSEC source: 0000899243-20-012754 · doc4.xml · derivative · entry 6 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,750 shares Expires 2020-08-06 F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. Read SEC document |
| May 08, 2020 Filed May 11, 2020 21:48 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerStock Options · Derivative | 509 | $0.00 Strike: $196.16 | $0.00 |
DisclosureSEC source: 0000899243-20-012754 · doc4.xml · derivative · entry 5 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 509 shares Expires 2020-08-06 F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. Read SEC document |
| May 08, 2020 Filed May 11, 2020 21:48 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerStock Options · Derivative | 3,852 | $0.00 Strike: $103.79 | $0.00 |
DisclosureSEC source: 0000899243-20-012754 · doc4.xml · derivative · entry 4 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,852 shares Expires 2020-08-06 F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. Read SEC document |
| May 08, 2020 Filed May 11, 2020 21:48 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerStock Options · Derivative | 16,524 | $0.00 Strike: $224.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012754 · doc4.xml · derivative · entry 3 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 16,524 shares Expires 2023-05-08 F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020. F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement. Read SEC document |
| May 08, 2020 Filed May 11, 2020 21:48 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerRestricted Stock Units | 16,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012754 · doc4.xml · nonDerivative · entry 2 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · balance_after: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement. Read SEC document |
| May 08, 2020 Filed May 11, 2020 21:48 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerOrdinary Shares, par value $0.0001 | 17,629.307 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012754 · doc4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 18:28 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 581 | $175.71 | $102,087.51 |
DisclosureSEC source: 0001179110-20-004761 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,427.307 F1 · balance_after: Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 14:17 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 14,444 | $193.84 | $2,799,824.96 |
DisclosureSEC source: 0001179110-20-003040 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,008.307 F1 · balance_after: Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 17:51 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 1,313 | $191.17 | $251,006.21 |
DisclosureSEC source: 0001179110-20-000041 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,564.307 F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 15:14 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 581 | $145.71 | $84,657.51 |
DisclosureSEC source: 0001179110-19-004796 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,877.307 F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 15:48 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 1,464 | $133.66 | $195,678.24 |
DisclosureSEC source: 0001179110-19-000194 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,458.307 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 18:59 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 581 | $164.74 | $95,713.94 |
DisclosureSEC source: 0000903423-18-000202 · baileyf4.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,922.307 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 16:39 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 1,136 | $163.58 | $185,826.88 |
DisclosureSEC source: 0001179110-18-000113 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,503.307 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:41 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionPerformance Based Restricted Share Unit · Derivative | 7,988 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-013557 · edgar.xml · derivative · entry 4 Bailey A Robert D · CIK 0001591683 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,988 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F4 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F4 · derivative.exercise_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F4 · derivative.expiration_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:41 UTC | Allergan plc AGN · Entity 149298 | Exercise / conversionOrdinary Shares, par value $0.0001 | 7,988 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-013557 · edgar.xml · nonDerivative · entry 3 Bailey A Robert D · CIK 0001591683 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,639.307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019. F4 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person. F5 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| June 16, 2017 Filed Oct 30, 2017 21:41 UTC | Allergan plc AGN · Entity 149298 | OtherOrdinary Shares, par value $0.001 | 2.185 | $235.96 | $515.57 |
DisclosureSEC source: 0001179110-17-013557 · edgar.xml · nonDerivative · entry 2 Bailey A Robert D · CIK 0001591683 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,651.307 F2 · balance_after: Includes shares reported on previously-filed Form 4s on April 4, 2017 and May 16, 2017, and includes 2.1850 shares acquired on June 16, 2017 pursuant to a broker-assisted dividend reinvestment plan. F5 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| May 15, 2017 Filed May 16, 2017 18:09 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 456 | $228.22 | $104,068.32 |
DisclosureSEC source: 0001179110-17-007336 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,647 F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:25 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 5,890 | $237.68 | $1,399,935.20 |
DisclosureSEC source: 0001179110-17-005555 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,103 F1 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty percent (20%) on April 3, 2018, twenty percent (20%) on April 3, 2019, twenty percent (20%) on April 3, 2020, twenty percent (20%) on April 3, 2021 and twenty percent (20%) on April 3, 2022. F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| March 29, 2017 Filed Oct 30, 2017 21:41 UTC | Allergan plc AGN · Entity 149298 | OtherOrdinary Shares, par value $0.001 | 2.122 | $242.21 | $513.97 |
DisclosureSEC source: 0001179110-17-013557 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,215.122 F1 · balance_after: Includes 2.1220 shares acquired on March 29, 2017 pursuant to a broker-assisted dividend reinvestment plan. F5 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| November 12, 2016 Filed Nov 15, 2016 17:17 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 702 | $207.57 | $145,714.14 |
DisclosureSEC source: 0001179110-16-031624 · edgar.xml · nonDerivative · entry 1 Bailey A Robert D · CIK 0001591683 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,213 F1 · balance_after: Includes restricted shares pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.